
MilliporeSigma boosts drug substance production capacity with new facility in France
At MilliporeSigma’s site in Matillac, France, the CDMO has opened a new 29,000-square-foot facility that will boost its ability to produce drug substance for monoclonal antibody treatments. (MilliporeSigma)